Pro-Dex (FRA:PDXN) ROCE %: 40.39% (As of Mar. 2026)

What is Pro-Dex ROCE %?

Pro-Dex FRA:PDXN 66 ROCE % is 40.39% as of Mar. 2026. GuruFocus rates FRA:PDXN with a GF Score™ of 66/100 and a GF Value™ of €37.92 (Significantly Overvalued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pro-Dex's annualized ROCE % for the quarter that ended in Mar. 2026 was 40.39%.

Pro-Dex (FRA:PDXN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pro-Dex ROCE % Related Terms

Pro-Dex ROCE % Historical Data

* Premium members only.

The historical data trend for Pro-Dex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro-Dex ROCE % Chart

Pro-Dex Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

ROCE %

Get a 7-Day Free Trial

25.80

18.21

24.65

7.84

28.97

Pro-Dex Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															42.39	15.28	52.39	24.40	40.39

66GF Score

Pro-Dex Inc FRA:PDXN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pro-Dex ROCE % Calculation

Pro-Dex's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	11.173	/	( ( (48.751 - 11.977)	+	(53.053 - 12.683) )	/ 2 )
	=	11.173	/	( (36.774	+	40.37)	/ 2 )
	=	11.173	/	38.572
	=	28.97 %

Pro-Dex's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	19.172	/	( ( (53.167 - 10.42)	+	(64.855 - 12.66) )	/ 2 )
	=	19.172	/	( ( 42.747	+	52.195 )	/ 2 )
	=	19.172	/	47.471
	=	40.39 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 40.39% mean?

Pro-Dex (FRA:PDXN) has a ROCE % of 40.39% as of Mar. 2026.

Is Pro-Dex's ROCE % too high?

Pro-Dex's current ROCE % is 40.39%. The Medical Devices & Instruments industry median ROCE % is 2.23. Pro-Dex's value of 40.39% is 1711.2% above this industry median. Overall, Pro-Dex has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Pro-Dex's ROCE % compare to SMTI and UTMD?

Pro-Dex's ROCE % of 40.39% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Pro-Dex's value of 40.39% is 1711.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro-Dex's current ROCE % of 40.39% is 1711.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current ROCE % is 40.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pro-Dex stock overvalued right now?

Based on GuruFocus' analysis, Pro-Dex (FRA:PDXN) is currently considered Significantly Overvalued. The stock's GF Value™ is €37.92, compared to a current price of €57.00 — trading 50.3% above its estimated fair value. The current ROCE % is 40.39% and 1711.2% above the Medical Devices & Instruments industry median of 2.23. Pro-Dex's overall GF Score™ is 66/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Pro-Dex (FRA:PDXN), the current ROCE % is 40.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pro-Dex (FRA:PDXN) Overvalued in 2026?

Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued. The current stock price of €57.00 is trading 50.3% above its estimated GF Value™ of €37.92. GuruFocus considers Pro-Dex to be Significantly Overvalued.

Key valuation signals for FRA:PDXN:

ROCE %: 40.39%
GF Value™: €37.92 vs. price of €57.00 (50.3% above fair value)
GF Score™: 66/100 with 10 warning signs
Industry Position: 1711.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:PDXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pro-Dex Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies SMTI UTMD EMBC STXS KRMD MBOT OSUR DXR POCI NEPH ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges PDEX:USA

Address 2361 McGaw Avenue, Irvine, CA, USA, 92614

Website https://www.pro-dex.com

Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.

66GF Score

Get the complete analysis for FRA:PDXN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€57.00

Price

€37.92

GF Value

View FRA:PDXN Analysis

See ROCE % data for all stocks →